Eisai Co., Ltd. (ESALF)
OTCMKTS · Delayed Price · Currency is USD
26.76
+1.74 (6.50%)
Feb 10, 2026, 9:30 AM EST
Eisai Company Description
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals.
It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas.
The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955.
Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Eisai Co., Ltd.
| Country | Japan |
| Founded | 1941 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 10,917 |
| CEO | Haruo Naito |
Contact Details
Address: 4-6-10 Koishikawa Tokyo, 112-8088 Japan | |
| Phone | 81 3 3817 3700 |
| Website | eisai.co.jp |
Stock Details
| Ticker Symbol | ESALF |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | JPY |
| ISIN Number | JP3160400002 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Haruo Naito | Chief Executive Officer, Representative Corporate Officer and Director |
| Gary Hendler | Senior Vice President and President of EMEA Region |
| Dr. Lynn D. Kramer FAAN, M.D. | Vice President and Chief Clinical Officer |
| Yanhui Feng | Senior Vice President |
| Takuya Oyama | Vice President, Chief Financial Officer and Chief IR Officer |
| Keisuke Naito | Representative Corporate Officer, EVice President, Chief Operating Officer and Chief Growth Officer |
| Akiko Nakahama | Vice President of Japan Regulatory Affairs, Manufacturing, Quality and Technology |
| Makoto Hoketsu | Vice President and Chief Information Officer |
| Dr. Katsutoshi Ido | Vice President, Chief Scientific Officer and Head of DHBL Discoverry |
| Shin Kato | Vice President, General Counsel and Chief Compliance Officer |